$599

Zealand 2025 CMD and Partnership for Obesity Drug Discovery; Lilly Shares Topline Retatrutide Results; Corbus Topline CB1 Data; Dexcom Launches G7 15 Day CGM; Prolynx Series A Funding and Names CEO

A series of cardiometabolic-related news items has been observed from Zealand Pharma, Lilly, Corbus Pharmaceuticals, Dexcom, and Prolynx. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here